Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (144)	10/5/2000 11:00:30 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 362

Stuart, Harry: I had in mind something like ALKS Medisorb technology, Risperdal and Naltrexone formulation. Risperdal-depot (currently at two PIII trials, J&J) seams OK (I do not have any idea on their PII results) based on J&J commitment for PIII trials. Interesting is that, while I do not have cleat picture can this formulation deliver continuous drug effective plasma level for extended period, ALKS is very serious about this formulation. Manufacturing facility is operational. Harry, any info about Risperdal-depot results so far? Miljenko